Albumin Market Synopsis

Albumin Market Size Was Valued at USD 6.01 Billion in 2023, and is Projected to Reach USD 12.02 Billion by 2032, Growing at a CAGR of 8.01% From 2024-2032

Albumin is a protein found in the blood plasma that plays a crucial role in maintaining the body's fluid balance and transporting various substances, such as hormones, drugs, and fatty acids. It's primarily produced by the liver and contributes significantly to the regulation of osmotic pressure in the blood, helping to prevent fluid from leaking out of blood vessels. Due to its properties, albumin has diverse applications in medicine and research.

• In the medical field, albumin is commonly used as a plasma expander to treat conditions like hypovolemia (low blood volume) or shock. Its ability to increase blood volume swiftly makes it valuable in emergency situations. Additionally, albumin finds application in drug delivery systems, stabilizing and delivering medications. In research, it serves as a standard protein for various biochemical studies, including electrophoresis and protein assays.
• As for market trends, albumin continues to be in demand across pharmaceutical and research sectors. The market growth is influenced by the rising incidence of diseases requiring albumin-based treatments, such as liver diseases and burns. Furthermore, advancements in biotechnology have led to the development of recombinant albumin, providing a more stable and cost-effective alternative to human serum albumin, driving its market expansion. Additionally, ongoing research exploring albumin's potential in targeted drug delivery and as a biomarker for various diseases contributes to its increasing relevance and demand in the healthcare industry.

Albumin Market Trend Analysis

Growing Geriatric Population

• As demographics shift and life expectancy rises, there's a parallel increase in age-related health concerns. Elderly individuals commonly encounter conditions such as chronic kidney diseases, liver disorders, and various chronic ailments where maintaining adequate albumin levels becomes crucial for managing these health issues effectively.
• The physiological changes in older adults often lead to decreased albumin levels in the body, resulting in conditions such as hypoalbuminemia. Consequently, there's a heightened demand for albumin-based therapies to address these deficiencies and related complications among the elderly.
• Moreover, the aging population experiences a higher incidence of conditions requiring albumin supplementation, such as severe burns or trauma, where albumin's role in fluid management and tissue repair becomes vital for recovery.
• With the global demographic landscape leaning toward an increasingly older population, the demand for albumin-based treatments is anticipated to surge correspondingly. This demographic shift underscores the importance of albumin in managing health concerns prevalent among the elderly, solidifying its position as a critical component in addressing various age-related medical conditions.

Research and Development Initiatives

• Ongoing R&D endeavours focus on uncovering novel uses for albumin beyond its conventional roles. Scientists are investigating its efficacy in targeted drug delivery systems, where albumin serves as a carrier for therapeutic molecules, enhancing drug stability and bioavailability while reducing side effects. Additionally, researchers are exploring albumin's potential in regenerative medicine, tissue engineering, and wound healing due to its unique properties that support cell growth and tissue repair.
• Moreover, studies aim to establish albumin's role as a biomarker for various diseases, potentially revolutionizing diagnostic methods. By identifying specific albumin patterns or levels associated with certain health conditions, researchers strive to develop diagnostic tools for early disease detection and monitoring.
• Collaborations between academia, pharmaceutical companies, and research institutions foster an environment conducive to breakthrough discoveries, paving the way for innovative albumin-based therapies and applications. The cumulative effect of these R&D initiatives not only broadens the understanding of albumin's capabilities but also presents opportunities for the development of new treatment modalities, driving market expansion and offering promising avenues for healthcare advancement.

Albumin Market Segment Analysis:

Albumin Market Segmented on the basis of type and application.

By Type, Human Serum Albumin segment is expected to dominate the market during the forecast period

• The Human Serum Albumin (HSA) segment is poised to maintain its dominance in the albumin market throughout the forecast period. HSA, derived from human blood plasma, holds a significant share due to its extensive usage in various therapeutic applications, including treating hypoalbuminemia, shock, burns, and liver diseases.
• The reliability and efficacy of HSA in clinical settings, coupled with its long-standing approval and acceptance, contribute to its sustained dominance. Its ability to efficiently manage conditions where maintaining or restoring adequate albumin levels is crucial reinforces its market position.
• Furthermore, while recombinant albumin variants are emerging and gaining attention due to their advantages in stability and cost-effectiveness, HSA remains the primary choice for many medical applications. Its established safety profile and widespread availability continue to drive its prominence, indicating that HSA will likely continue as the leading segment in the albumin market during the projected period.

By Application, Therapeutics segment held the largest market share of 42% in 2022

• In the albumin market, the Therapeutics segment has consistently commanded the largest market share due to the extensive and varied therapeutic applications of albumin. Albumin serves as a vital component in treating a spectrum of medical conditions, contributing significantly to this segment's dominance.
• Therapeutically, albumin finds widespread use in managing hypoalbuminemia, a condition characterized by low levels of albumin in the blood, often associated with chronic illnesses like liver diseases, kidney disorders, and malnutrition. Additionally, its role as a plasma expander in emergency situations such as shock and trauma further solidify its position within the therapeutics segment.
• The versatility of albumin in these therapeutic applications, coupled with its ability to address critical medical needs like maintaining blood volume and providing essential proteins, underscores its prominence in this segment. As a result, the Therapeutics segment continues to hold the largest market share, reflecting the indispensability of albumin in various crucial medical treatments and therapies.

Albumin Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• The Asia Pacific region is anticipated to emerge as the dominant force in the albumin market over the forecast period. Several factors contribute to this projected dominance, including increasing healthcare expenditure, rising prevalence of chronic diseases requiring albumin-based therapies, and expanding access to healthcare services across the region.
• Countries in the Asia Pacific are witnessing a significant rise in the geriatric population, leading to a higher incidence of age-related conditions where albumin plays a crucial role in treatment. Moreover, advancements in healthcare infrastructure, along with a growing focus on research and development initiatives, are propelling the demand for albumin-based therapies in the region.
• Furthermore, the presence of key market players focusing on expanding their presence and investing in the Asia Pacific region, along with favorable government initiatives and policies, contributes to the anticipated dominance. As a result, the Asia Pacific region is expected to lead the albumin market during the forecast period, driven by increasing healthcare needs, expanding healthcare infrastructure, and a growing emphasis on innovative medical solutions.

Albumin Market Top Key Players:

• Albumedix Ltd. (UK)
• Albumin Bioscience(US)
• Biotest AG (Germany)
• CSL Behring (US)
• Grifols International SA (Spain)
• HiMedia Laboratories Pvt. Ltd. (India)
• InVitria (US)
• Medxbio Pte. Ltd. (Singapore)
• MilliporeSigma (US)
• Octapharma AG (Switzerland)
• RayBiotech Inc. (Georgia)
• Seracare Life Sciences Inc. (the US)
• Akron Biotech (US)
• Bristol-Myers Squibb Company (US) and Other Major Players

Key Industry Developments in the Albumin Market:

• In July 2023, Kedrion Biopharma announced that China's National Institutes for Food and Drug Control (NIFDC) had approved BPL's human Albumin product for release into the Chinese market for therapeutic use.
• In July 2023, Grifols S.A., a leading manufacturer of plasma-derived medicines, announced the phase 3 completion of PRECIOSA to determine the potential of long-term albumin-based treatment with Grifols S.A.’s Albutein. The clinical study aims to increase the survival time of patients suffering from decompensated cirrhosis and ascites until a suitable transplant is available.
• In December 2022, CSL opened a new plasma fractionation facility in Australia to fractionate human plasma to treat haemophilia, immune system problems, burns, and other life-threatening medical conditions. This move allowed Australia to step forward in medicine by introducing a plasma fractionation plant capable of producing nine million litres of plasma per year.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. ALBUMIN MARKET BY TYPE (2016-2030)
   1. ALBUMIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HUMAN SERUM ALBUMIN
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. BOVINE SERUM
   5. RECOMBINANT ALBUMIN
7. ALBUMIN MARKET BY APPLICATION (2016-2030)
   1. ALBUMIN MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. THERAPEUTICS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. DRUG FORMULATION & VACCINES
   5. COMPONENT OF MEDIA
8. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. ALBUMIN Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. ALBUMEDIX LTD. (UK)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. ALBUMIN BIOSCIENCE (US)
   4. BIOTEST AG (GERMANY)
   5. CSL BEHRING (US)
   6. GRIFOLS INTERNATIONAL SA (SPAIN)
   7. HIMEDIA LABORATORIES PVT. LTD. (INDIA)
   8. INVITRIA (US)
   9. MEDXBIO PTE. LTD. (SINGAPORE)
   10. MILLIPORESIGMA (US)
   11. OCTAPHARMA AG (SWITZERLAND)
   12. RAYBIOTECH INC. (GEORGIA)
   13. SERACARE LIFE SCIENCES INC. (THE US)
   14. AKRON BIOTECH (US)
   15. BRISTOL-MYERS SQUIBB COMPANY (US)
9. GLOBAL ALBUMIN MARKET BY REGION
   1. OVERVIEW
   2. NORTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By TYPE
      4. Historic And Forecasted Market Size By APPLICATION
      5. Historic And Forecasted Market Size By Country
         1. USA
         2. Canada
         3. Mexico
   3. EASTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Russia
         2. Bulgaria
         3. The Czech Republic
         4. Hungary
         5. Poland
         6. Romania
         7. Rest Of Eastern Europe
   4. WESTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Germany
         2. United Kingdom
         3. France
         4. The Netherlands
         5. Italy
         6. Spain
         7. Rest Of Western Europe
   5. ASIA PACIFIC
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Malaysia
         6. Thailand
         7. Vietnam
         8. The Philippines
         9. Australia
         10. New-Zealand
         11. Rest Of APAC
   6. MIDDLE EAST & AFRICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Turkey
         2. Bahrain
         3. Kuwait
         4. Saudi Arabia
         5. Qatar
         6. UAE
         7. Israel
         8. South Africa
   7. SOUTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
         1. Brazil
         2. Argentina
         3. Rest of South America
10. INVESTMENT ANALYSIS
11. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ALBUMIN MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ALBUMIN MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ALBUMIN MARKET COMPETITIVE RIVALRY
TABLE 005. ALBUMIN MARKET THREAT OF NEW ENTRANTS
TABLE 006. ALBUMIN MARKET THREAT OF SUBSTITUTES
TABLE 007. ALBUMIN MARKET BY PRODUCT
TABLE 008. RECOMBINANT ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 009. BOVINE SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 010. HUMAN SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 011. ALBUMIN MARKET BY APPLICATION
TABLE 012. INGREDIENT IN CULTURE MEDIA MARKET OVERVIEW (2016-2028)
TABLE 013. VACCINE INGREDIENT MARKET OVERVIEW (2016-2028)
TABLE 014. THERAPEUTICS & DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 016. ALBUMIN MARKET BY END-USERS
TABLE 017. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 018. PHARMACEUTICAL MARKET OVERVIEW (2016-2028)
TABLE 019. BIOTECHNOLOGY INDUSTRY MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 021. NORTH AMERICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 022. NORTH AMERICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 023. N ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 025. EUROPE ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 026. EUROPE ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 027. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 029. ASIA PACIFIC ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 030. ASIA PACIFIC ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 031. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 035. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 037. SOUTH AMERICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 038. SOUTH AMERICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 039. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 040. ALBUMEDIX LTD.: SNAPSHOT
TABLE 041. ALBUMEDIX LTD.: BUSINESS PERFORMANCE
TABLE 042. ALBUMEDIX LTD.: PRODUCT PORTFOLIO
TABLE 043. ALBUMEDIX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. ALBUMIN BIOSCIENCE: SNAPSHOT
TABLE 044. ALBUMIN BIOSCIENCE: BUSINESS PERFORMANCE
TABLE 045. ALBUMIN BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 046. ALBUMIN BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. BIOTEST AG: SNAPSHOT
TABLE 047. BIOTEST AG: BUSINESS PERFORMANCE
TABLE 048. BIOTEST AG: PRODUCT PORTFOLIO
TABLE 049. BIOTEST AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. CSL BEHRING: SNAPSHOT
TABLE 050. CSL BEHRING: BUSINESS PERFORMANCE
TABLE 051. CSL BEHRING: PRODUCT PORTFOLIO
TABLE 052. CSL BEHRING: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. GRIFOLS INTERNATIONAL SA: SNAPSHOT
TABLE 053. GRIFOLS INTERNATIONAL SA: BUSINESS PERFORMANCE
TABLE 054. GRIFOLS INTERNATIONAL SA: PRODUCT PORTFOLIO
TABLE 055. GRIFOLS INTERNATIONAL SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. HIMEDIA LABORATORIES PVT. LTD.: SNAPSHOT
TABLE 056. HIMEDIA LABORATORIES PVT. LTD.: BUSINESS PERFORMANCE
TABLE 057. HIMEDIA LABORATORIES PVT. LTD.: PRODUCT PORTFOLIO
TABLE 058. HIMEDIA LABORATORIES PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. INVITRIA: SNAPSHOT
TABLE 059. INVITRIA: BUSINESS PERFORMANCE
TABLE 060. INVITRIA: PRODUCT PORTFOLIO
TABLE 061. INVITRIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. MEDXBIO PTE. LTD.: SNAPSHOT
TABLE 062. MEDXBIO PTE. LTD.: BUSINESS PERFORMANCE
TABLE 063. MEDXBIO PTE. LTD.: PRODUCT PORTFOLIO
TABLE 064. MEDXBIO PTE. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. MILLIPORESIGMA: SNAPSHOT
TABLE 065. MILLIPORESIGMA: BUSINESS PERFORMANCE
TABLE 066. MILLIPORESIGMA: PRODUCT PORTFOLIO
TABLE 067. MILLIPORESIGMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. OCTAPHARMA AG: SNAPSHOT
TABLE 068. OCTAPHARMA AG: BUSINESS PERFORMANCE
TABLE 069. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 070. OCTAPHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. RAYBIOTECH INC.: SNAPSHOT
TABLE 071. RAYBIOTECH INC.: BUSINESS PERFORMANCE
TABLE 072. RAYBIOTECH INC.: PRODUCT PORTFOLIO
TABLE 073. RAYBIOTECH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. SERACARE LIFE SCIENCES INC.: SNAPSHOT
TABLE 074. SERACARE LIFE SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 075. SERACARE LIFE SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 076. SERACARE LIFE SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. AKRON BIOTECH: SNAPSHOT
TABLE 077. AKRON BIOTECH: BUSINESS PERFORMANCE
TABLE 078. AKRON BIOTECH: PRODUCT PORTFOLIO
TABLE 079. AKRON BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. BRISTOL-MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 080. BRISTOL-MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 081. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 082. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 083. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 084. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 085. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ALBUMIN MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ALBUMIN MARKET OVERVIEW BY PRODUCT
FIGURE 012. RECOMBINANT ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 013. BOVINE SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 014. HUMAN SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 015. ALBUMIN MARKET OVERVIEW BY APPLICATION
FIGURE 016. INGREDIENT IN CULTURE MEDIA MARKET OVERVIEW (2016-2028)
FIGURE 017. VACCINE INGREDIENT MARKET OVERVIEW (2016-2028)
FIGURE 018. THERAPEUTICS & DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 020. ALBUMIN MARKET OVERVIEW BY END-USERS
FIGURE 021. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 022. PHARMACEUTICAL MARKET OVERVIEW (2016-2028)
FIGURE 023. BIOTECHNOLOGY INDUSTRY MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)